[Therapy monitoring in cardiac arrhythmias: guidelines for evaluation of anti-arrhythmia effects].
The incidence of avoidable or unavoidable, cardial and extracardial side effects is a risk in the drug treatment of supraventricular and ventricular tachyarrhythmias. Therefore the indication of antiarrhythmic drug therapy has to be considered critically. The patient has to be controlled close-meshed, especially at the beginning of the drug treatment. In patients with life threatening ventricular tachyarrhythmias, which can not be suppressed by drug therapy, nonpharmacological therapy--implantable cardioverter/defibrillator, catheterablation and heart-transplantation--has to be discussed.
Hief
C
C
III. Medizinischen Abteilung mit Kardiologie, Ludwig-Boltzmann-Institut für Arrhythmieforschung, Wilhelminenspitals, Wien.
Podczeck
A
A
Frohner
K
K
Nürnberg
M
M
Kaltenbrunner
W
W
Steinbach
K
K
D000889:Anti-Arrhythmia Agents / Q000009:adverse effects* / Q000145:classification / Q000627:therapeutic use; D003131:Combined Modality Therapy; D016903:Drug Monitoring; D004562:Electrocardiography / Q000187:drug effects; D006801:Humans; D017180:Tachycardia, Ventricular / Q000145:classification / Q000188:drug therapy* / Q000209:etiology; D016896:Treatment Outcome
D000889:Anti-Arrhythmia Agents
Therapiekontrolle bei Herzrhythmusstörungen: Richtlinien zur Prüfung antiarrhythmischer Wirkungen.